Specialty pharmacy and distributors list

LUMAKRAS® (sotorasib) 240 mg tablets

The LUMAKRAS® network gives providers and patients multiple dispensing options

Specialty Pharmacies (SPs)

In-office Dispensing Pharmacies

Specialty pharmacy network

LUMAKRAS® is available for order from these specialty pharmacies who also provide support to help patients with their prescribed treatments:

Specialty pharmacy	Phone number	Fax number
Biologics	800-850-4306	800-823-4506
CenterWell Specialty Pharmacy	800-720-7258	877-405-7940
AcariaHealth	407-903-1308	833-762-0871
Onco 360	877-662-6633	877-662-6355
Optum Specialty Pharmacy	877-445-6874	877-342-4596
Accredo Health Group	For patients: 877-732-3431 MDO ONLY: 877-783-2262	866-352-3973
CVS Specialty	888-280-1193	855-296-0210

- Check with your patient's insurance for specific coverage requirements and specialty pharmacy mandates.
- Payer and Pharmacy Benefit Manager (PBM) specialty pharmacy mandates may apply regardless of the manufacturer-defined specialty pharmacy network.

Specialty distributors network

These authorized specialty distributors stock and sell LUMAKRAS®:

Specialty distributor	Phone number	Website
ASD Healthcare	800-837-5403	www.asdhealthcare.com
Oncology Supply	800-633-7555	www.oncologysupply.com
Cardinal Health SPD – Hospital & SP's	855-855-0708	www.cardinalhealth.com
Cardinal Health SPD - Clinics	877-453-3972	www.cardinalhealth.com
McKesson Plasma and Biologics	877-625-2566	connect.mckesson.com
McKesson Specialty Care Distribution	855-477-9800	mscs.mckesson.com/CustomerCenter

This table is current as of 01/27/2023.

The specialty pharmacies and distributors identified can fill and distribute LUMAKRAS® and are provided herein for informational purposes only and is not an endorsement or recommendation to use any particular pharmacy or distributor over another. This list may not be exhaustive and is subject to change. It represents no statement, promise, or guarantee by Amgen Inc. concerning coverage and/or availability of the product for any particular patient and it is the responsibility of the health care provider to determine the appropriate services provided to their patients.

MDO, Medical Doctor's Office; PBM, Pharmacy Benefit Manager; SPD, Specialty Pharmacy Distribution.

Please see page 2 for Indication and LUMAKRAS® Important Safety Information. Click here for LUMAKRAS® full Prescribing Information.

INDICATION AND IMPORTANT SAFETY INFORMATION

Indication

LUMAKRAS® is indicated for the treatment of adult patients with *KRAS G12C*-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Important Safety Information

Hepatotoxicity

- LUMAKRAS can cause hepatotoxicity and increased ALT or AST which may lead to drug-induced liver injury and hepatitis.
- In the pooled safety population of NSCLC patients who received single agent LUMAKRAS 960 mg hepatotoxicity occurred in 27% of patients, of which 16% were Grade ≥ 3. Among patients with hepatotoxicity who required dosage modifications, 64% required treatment with corticosteroids.
- In this pooled safety population of NSCLC patients who received single agent LUMAKRAS 960 mg, 17% of patients who received LUMAKRAS had increased alanine aminotransferase (ALT)/increased aspartate aminotransferase (AST); of which 9% were Grade ≥ 3. The median time to first onset of increased ALT/AST was 6.3 weeks (range: 0.4 to 42). Increased ALT/AST leading to dose interruption or reduction occurred in 9% of patients treated with LUMAKRAS. LUMAKRAS was permanently discontinued due to increased ALT/AST in 2.7% of patients. Drug-induced liver injury occurred in 1.6% (all grades) including 1.3% (Grade ≥ 3).
- In this pooled safety population of NSCLC patients who received single agent LUMAKRAS 960 mg, a total of 40% patients with recent (≤ 3 months) immunotherapy prior to starting LUMAKRAS had an event of hepatotoxicity. An event of hepatotoxicity was observed in 18% of patients who started LUMAKRAS more than 3 months after last dose of immunotherapy and in 17% of those who never received immunotherapy. Regardless of time from prior immunotherapy, 94% of hepatotoxicity events improved or resolved with dosage modification of LUMAKRAS, with or without corticosteroid treatment.
- Monitor liver function tests (ALT, AST, alkaline phosphatase and total bilirubin) prior to the start of LUMAKRAS, every 3 weeks for the first 3 months of treatment, then once a month or as clinically indicated, with more frequent testing in patients who develop transaminase and/or bilirubin elevations. Withhold, reduce the dose or permanently discontinue LUMAKRAS based on severity of the adverse reaction. Consider administering systemic corticosteroids for the management of hepatotoxicity.

Interstitial Lung Disease (ILD)/Pneumonitis

- LUMAKRAS can cause ILD/pneumonitis that can be fatal.
- In the pooled safety population of NSCLC patients who received single agent LUMAKRAS 960 mg ILD/pneumonitis occurred in 2.2% of patients, of which 1.1% were Grade ≥ 3, and 1 case was fatal. The median time to first onset for ILD/pneumonitis was 8.6 weeks (range: 2.1 to 36.7 weeks). LUMAKRAS was permanently discontinued due to ILD/pneumonitis in 1.3% of LUMAKRAS-treated patients. Monitor patients for new or worsening pulmonary symptoms indicative of ILD/pneumonitis (e.g., dyspnea, cough, fever). Immediately withhold LUMAKRAS in patients with suspected ILD/pneumonitis and permanently discontinue LUMAKRAS if no other potential causes of ILD/pneumonitis are identified.

Most Common Adverse Reactions

- The most common adverse reactions ≥ 20% were diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, and cough.

Drug Interactions

- Advise patients to inform their healthcare provider of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, dietary and herbal products.
- Inform patients to avoid proton pump inhibitors and H_2 receptor antagonists while taking LUMAKRAS®.
- If coadministration with an acid-reducing agent cannot be avoided, inform patients to take LUMAKRAS® 4 hours before or 10 hours after a locally acting antacid.

Please see LUMAKRAS® full Prescribing Information.

Reference: LUMAKRAS® (sotorasib) prescribing information, Amgen.

For more information, visit LUMAKRASHCP.com

AMGEN

LUMAKRAS® (sotorasib) 240 mg tablets

Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
www.amgen.com

© 2025 Amgen Inc. All rights reserved.
USA-510-81949 09/25